2020
AWESOME POWER OF HAP1 CELLS
The Arnesen lab embraced CRISPR-targeted HAP1 cells, approximately five years ago, leading amongst other things to the discovery of the actin N-terminal acetyltransferase, NAA80, and its associated phenotypes.
Novel NAA10 VARIANTS
Several variants of the NAA10 gene have been found in patients suffering from developmental delay and hemihypertrophy.
NAA80 IS ASSISTED BY PROFILIN 2
Actin is modified by N-terminal acetylation which regulates its role in steering cellular architecture and cell motility. Now the machinery performing this acetylation is uncovered.
RESEARCH FROM HOME
On Thursday 12th of March, UiB was shut down on short notice due to the world pandemic. Here, three members of the Arnesen group share their home office experience.
DIVERSITY OUR STRENGTH
Researcher Sylvia Varland was seeking new challenges with a potential stint abroad, after graduating with a PhD from the Arnesen lab at UiB.
AKSNES RECEIVES FALCH JUNIOR AWARD
The Consul Søren Falch and ophthalmologist Sigurd Falch's junior prize for young researcher 2020 was awarded jointly to Henriette Aksnes and Marte-Helene Bjørk.
MECHANISM OF A CELL MOTILITY REGULATOR
Recently, UiB researchers identified NAA80 as a long-sought actin regulator. Now, the structure of NAA80 bound to actin and profilin reveals its mechanism of action.
FROM ERASMUS INTERNSHIP TO PUBLISHED PAPER
During an Erasmus internship and master project in the Arnesen group, Tobias B. Beigl investigated why cells lacking NAA80 typically have a more fragmented Golgi apparatus.
ENZYME UPREGULATED IN CANCERS DISSECTED BY UPENN AND UIB RESEARCHERS
Research groups at the UiB and University of Pennsylvania solved the structure and biochemical features of the human tetrameric NAA15-NAA10-NAA50-HYPK complex.